# KLOW Peptide Dosage Research Context: Composition and Component PK > KLOW peptide dosage context from the published research: the canonical 80 mg vial split, per-component pharmacokinetics, the PK mismatch, and routes studied. No human dosing recommendations — research context only. ## In plain English There is no validated human dose for KLOW peptide — and there cannot be one until the four-peptide blend is studied in humans, which has not happened. What this page documents is the composition of the research vial as listed across independent sources, the per-component pharmacokinetic (how-long-it-stays-in-the-body) data from the published literature, and what routes have been used in component research. The single most important pharmacokinetic fact: BPC-157, the angiogenic component, has a formal elimination half-life of under approximately 30 minutes in rats and dogs. The two tripeptides — KPV and GHK-Cu — are even smaller molecules and are also known to clear rapidly. This means a single vial of the co-formulated blend cannot hold all four components at matched plasma levels at the same time. The components will not all be 'working' simultaneously in equal measure. This reference describes what was measured in research; it does not recommend any dose, frequency, or protocol. ## KLOW peptide dosage — the research vial composition The canonical research vial composition — the most widely listed across independent compounders who supply lyophilized KLOW for laboratory use — is: - GHK-Cu: 50 mg (~62.5% of total by mass — the mass-dominant component) - BPC-157: 10 mg - TB-500: 10 mg - KPV: 10 mg - Total: 80 mg This vial is reconstituted with bacteriostatic water (sterile water containing a small amount of benzyl alcohol to prevent bacterial growth) for laboratory handling. No component-level rationale for this specific 50/10/10/10 split has been published; it appears to be a convention rather than a study-derived dosing schedule. The blend has no pharmacopeial monograph. No FDA-approved formulation of KLOW or any subset of these four components (as a combination) exists. The composition is a research-chemical co-formulation only. ## KLOW dosage — component-level pharmacokinetics (the PK mismatch table) The four components have markedly different reported half-lives and clearance characteristics. This table summarizes the published data: **BPC-157:** Elimination half-life under approximately 30 minutes in the formal rat/dog ADME study; intramuscular bioavailability approximately 14-19% in rats, approximately 45-51% in dogs; excretion via urine and bile; linear pharmacokinetics across dose ranges studied [8]. This is the most precisely characterized component from a pharmacokinetic standpoint. **GHK-Cu:** A rat HPLC pharmacokinetic study established rapid degradation of free GHK to the dipeptide HK (histidyl-lysine) after intravenous administration, consistent with rapid peptidase cleavage [9]. No validated human half-life exists. The copper(II) ion it carries has its own metabolic fate separate from the tripeptide scaffold. **KPV:** No formal published pharmacokinetic study for the isolated tripeptide after systemic injection. PepT1 (SLC15A1)-mediated uptake into intestinal epithelial and immune cells — with a Km of approximately 160 micromolar — is the primary documented uptake route, relevant to gut-targeted delivery. As a small tripeptide (MW 342.44 Da), rapid peptidase clearance from plasma is expected [3]. **TB-500 (Ac-LKKTETQ):** An analytical detection study established the compound in equine plasma/urine (LOD 0.01-0.02 ng/mL) [10] but has not characterized its half-life after subcutaneous injection. The native protein thymosin beta-4 is larger (43 amino acids; MW approximately 4.9 kDa for the native protein) and its pharmacokinetics differ from the short heptapeptide fragment. TB-500's precise systemic half-life after injection is not documented in peer-reviewed literature. The practical consequence: in a co-dissolved 80 mg research vial, BPC-157 begins clearing within 30 minutes and the tripeptides likely clear at a similar or faster rate. No dosing interval or vial-split modification has been formally studied that would equalize the in-vivo exposures of all four components. ## KLOW peptide dosage and frequency — what is and is not known Human clinical data for the blend does not exist. Summarizing what the component literature does and does not support: GHK-Cu: the most extensive human data is topical — a documented clinical literature for skin care and wound-care applications with controlled trials. Systemic human PK data for injectable GHK-Cu is minimal. BPC-157: a 2025 human IV pilot administered 10-20 mg intravenously in two adults [6]. Animal studies used intraperitoneal doses in the microgram-per-kilogram range (10 μg/kg was the dose that accelerated Achilles tendon healing in the Staresinic 2003 study [2]). Subcutaneous and intramuscular routes have also been investigated in animals. No human subcutaneous or intramuscular dose-response study has been conducted. Thymosin beta-4 (native protein, distinct from the TB-500 fragment): animal wound studies used topical doses as low as 10 pg for keratinocyte migration stimulation [1]; the acute-MI clinical trial used injectable study-specific doses [13]. These are NOT applicable to TB-500, the short fragment. KPV: animal colitis studies used 100 micromolar in drinking water [3]. In-vitro activity was observed at nanomolar concentrations. No human injectable dose-response data exists. Stability note: the lyophilized blend is typically refrigerated. Copper(II) in GHK-Cu can participate in redox chemistry — a theoretical compatibility consideration when co-dissolved with the other peptides. This interaction has not been formally characterized for this mixture. ## Routes studied in the component literature The following routes appear in the single-component published literature. These describe research contexts only — not human administration protocols. - **Intraperitoneal (IP):** the most common route in BPC-157 and thymosin beta-4 rodent studies - **Subcutaneous:** used in BPC-157 rodent models and in thymosin beta-4 animal studies - **Intravenous:** BPC-157 human pilot (2025) [6]; GHK plasma PK rat study [9]; thymosin beta-4 acute-MI clinical trial [13] - **Topical:** thymosin beta-4 wound studies [1]; GHK-Cu skin and wound literature [4]; RGN-259 ophthalmic thymosin beta-4 [12] - **Oral/targeted delivery:** KPV colitis studies in mice [3]; PepT1-targeted KPV nanoparticles [14] - **Intra-articular:** noted in BPC-157 joint-repair research literature Component reconstitution for the research vial uses bacteriostatic water. The co-dissolved solution stability — particularly the copper redox chemistry in the presence of the peptide backbones — has not been formally characterized. --- A component-attributed literature reference on the four-peptide KLOW blend — each finding sourced to the specific peptide it was established for, the blend-level gap noted plainly.